Larimar Therapeutics Doses First Patient with Nomlabofusp in the Open Label Extension Trial for Treating Friedreich’s Ataxia
Shots:
- Larimar has dosed first patient with nomlabofusp in an open label extension (OLE) trial to treat Friedreich’s ataxia (FA)
- The P-II OLE trial assesses nomlabofusp’s (25mg, SC, daily) safety, tolerability, PK, frataxin levels in peripheral tissues & other exploratory PD markers incl. lipid profiles & gene expression data. The data generated will be compared to a synthetic control arm from the Friedreich's Ataxia Clinical Outcome Measures Study (FACOMS) database
- Furthermore, for OLE study’s dose escalation, results from 50mg arm of P-II dose exploration trial & 25mg arm of the OLE trial will be submitted to the US FDA for review due to the continued partial clinical hold. Initial OLE study data is anticipated in Q4’24
Ref: Larimar Therapeutics | Image: Larimar Therapeutics
Related News:- Larimar Therapeutics Reports the Results for Nomlabofusp in P-II Trial for the Treatment of Friedreich’s Ataxia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
